Rayner Intraocular Lenses Announces FDA Clearance of the RaySert PLUS - a new mini-incision injector
Posted on 10/10/2014
09 October 2014. Hove, United Kingdom. Rayner Intraocular Lenses Limited, the pioneering manufacturer and designer of intraocular lenses, today announces the launch of the company’s new injector, RaySert PLUS in the US market after receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA).
RaySert PLUS is designed for safe and effective implantation of the C-flex® Aspheric IOL.
Simple and controlled IOL delivery through a wound assisted 2.2mm clear cornea mini incision.
-ENDS-
Rayner, the pioneering intraocular lens (IOL) manufacturer has over 60 years of dedication to improving vision and the restoration of sight worldwide. Today, Rayner’s mission remains that of delivering innovative and clinically superior ophthalmic products that consistently respond to the expectations of our global customers and reward the profound trust placed in the Company to improve sight and quality of life.
Headquartered in Hove, East Sussex, United Kingdom, Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 70 countries and a direct sales team in the United Kingdom and Germany.
For questions or to schedule an interview with a Rayner representative, please contact Rayner at iol_enquiries@rayner.com
